Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 in Advanced or Metastatic ESCC
NCT07417735Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 3, randomised, open-label trial of CPO301 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Progression-Free Survival at 2 years and Overall Survival at 2 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07417735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417735.